Head-to-head evidence
Henagliflozin vs Sitagliptin
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline
Henagliflozin
Developed by Jiangsu Hengrui Pharmaceuticals
NCT03159052 · Phase 3 · status unknown
This was a randomized, quadruple-blind, placebo-controlled trial (n=450). The primary endpoint, HbA1c change at 24 weeks, was clearly met: both the 5 mg and 10 mg doses reduced HbA1c significantly more than placebo (p<.001 for each).
Next expected readout: December 2026 · NCT06448130 (registry estimate)
Sitagliptin · Januvia
Marketed by Merck & Co.
NCT00087516 · Phase 3 · completed
The trial randomized 741 participants to double-blind sitagliptin or placebo groups, providing a substantial controlled comparison. The primary endpoint, change in A1C at week 24, was statistically favorable for both sitagliptin doses (p<0.001), but A1C is a surrogate endpoint, so the evidence is rated moderate rather than strong.
Next expected readout: October 2026 · NCT07711171 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Henagliflozin's landscape · Sitagliptin's landscape